83 FR 26486 - National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 110 (June 7, 2018)

Page Range		26486-26487
FR Document		2018-12175

Federal Register, Volume 83 Issue 110 (Thursday, June 7, 2018)

[Federal Register Volume 83, Number 110 (Thursday, June 7, 2018)]
[Notices]
[Pages 26486-26487]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-12175]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Arthritis and Musculoskeletal and Skin 
Diseases; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Arthritis and Musculoskeletal and Skin 
Diseases Initial Review Group; Arthritis and Musculoskeletal and 
Skin Diseases Special Grants Review Committee.
    Date: June 13-14, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites, Chevy Chase Pavilion, 4300 Military Rd. 
NW, Washington, DC 20015.
    Contact Person: Helen Lin, Ph.D., Scientific Review Officer, 
NIH/NIAMS/RB, 6701 Democracy Blvd., Suite 800, Plaza One, Bethesda, 
MD 20817, 301-594-4952, [email protected].

    Name of Committee: Arthritis and Musculoskeletal and Skin 
Diseases Initial Review Group; Arthritis and Musculoskeletal and 
Skin Diseases Clinical Trials Review Committee.
    Date: June 19, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center, 
Bethesda, MD 20814.
    Contact Person: Nakia C Brown, Ph.D., Scientific Review Officer, 
6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-827-4905, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, 
Arthritis, Musculoskeletal and Skin Diseases Research, National 
Institutes of Health, HHS)


[[Page 26487]]


    Dated: June 1, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-12175 Filed 6-6-18; 8:45 am]
BILLING CODE 4140-01-P

26486 Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices

industry and investment industry in request. We also note that HHS will not Dated: June 1, 2018.
order to increase innovation and respond to questions about the policy Eric D. Hargan,
investment in the healthcare sector? issues raised in this request for Deputy Secretary, Department of Health and
2. How the workgroup should be information. HHS may or may not Human Services.
convened and structured, including choose to contact individual responders. [FR Doc. 2018–12234 Filed 6–6–18; 8:45 am]
what subsectors of the healthcare Such communications would only serve BILLING CODE 4150–03–P
economy should be invited to to further clarify written responses.
participate, and the most effective size. Contractor support personnel may be
How should the agency structure DEPARTMENT OF HEALTH AND
used to review the responses submitted
meetings or other engagements in order HUMAN SERVICES
under this request for information.
to best facilitate the exchange of
information and the presentation of Responses to this notice are not offers
National Institutes of Health
attendees’ individual perspectives? The and cannot be accepted by the
Department seeks comment on how Government to form a binding contract National Institute of Arthritis and
suitable attendees should be identified or issue a grant. Information obtained in Musculoskeletal and Skin Diseases;
and selected to attend and engage in an response to this request for information Notice of Closed Meetings
exchange of ideas about the may be used by the Government for
Department’s goals of increasing program planning on a non-attribution Pursuant to section 10(d) of the
innovation and investment in the basis. Respondents should not include Federal Advisory Committee Act, as
healthcare sector. any information that might be amended, notice is hereby given of the
3. HHS also seeks comment more considered proprietary or confidential. following meetings.
broadly on opportunities for increased This request for information should not The meetings will be closed to the
engagement and dialogue between HHS be construed as a commitment or public in accordance with the
and those focused on innovating and authorization to incur cost for which provisions set forth in sections
investing in the healthcare industry, reimbursement would be required or 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
including alternatives to the workgroup sought. All submissions become as amended. The grant applications and
structure discussed in this request for Government property and will not be the discussions could disclose
information. The Department is
returned. HHS may publicly post the confidential trade secrets or commercial
interested in comments that propose
comments received, or a summary property such as patentable material,
alternatives for developing a durable
thereof. While responses to this request and personal information concerning
and consistent approach to increase
for information do not bind HHS to any individuals associated with the grant
innovation and investment in the
further actions related to the response, applications, the disclosure of which
healthcare sector to improve the public
all comments may be posted online on would constitute a clearly unwarranted
health and wellbeing of Americans.
This is a request for information only. http://www.regulations.gov. invasion of personal privacy.
Respondents are encouraged to provide III. Collection of Information
Name of Committee: Arthritis and
complete but concise responses to any Musculoskeletal and Skin Diseases Initial
or all of the questions outlined above. This document does not impose Review Group; Arthritis and Musculoskeletal
This request for information is issued and Skin Diseases Special Grants Review
information collection requirements;
solely for information and planning Committee.
that is, reporting, recordkeeping or Date: June 13–14, 2018.
purposes; it does not constitute a notice third-party disclosure requirements. Time: 8:00 a.m. to 5:00 p.m.
of proposed rulemaking or request for This request for information constitutes Agenda: To review and evaluate grant
proposals, applications, proposal a general solicitation of comments. In applications.
abstracts, or quotations, nor does it Place: Embassy Suites, Chevy Chase
accordance with the implementing
suggest that the Department will Pavilion, 4300 Military Rd. NW, Washington,
regulations of the Paperwork Reduction
undertake any particular action in DC 20015.
response to comments. This request for Act of 1995 (PRA) at 5 CFR 1320.3(h)(4),
Contact Person: Helen Lin, Ph.D.,
information does not commit the United information subject to the PRA does not
Scientific Review Officer, NIH/NIAMS/RB,
States Government (‘‘Government’’) to generally include ‘‘facts or opinions 6701 Democracy Blvd., Suite 800, Plaza One,
contract for any supplies or services or submitted in response to general Bethesda, MD 20817, 301–594–4952, linh1@
make a grant award. Further, HHS is not solicitations of comments from the mail.nih.gov.
seeking proposals through this request public, published in the Federal Name of Committee: Arthritis and
for information and will not accept Register or other publications, Musculoskeletal and Skin Diseases Initial
unsolicited proposals. Respondents are regardless of the form or format thereof, Review Group; Arthritis and Musculoskeletal
advised that the Government will not provided that no person is required to and Skin Diseases Clinical Trials Review
pay for any information or supply specific information pertaining Committee.
administrative costs incurred in to the commenter, other than that Date: June 19, 2018.
response to this request for information; necessary for self-identification, as a Time: 8:00 a.m. to 5:00 p.m.
all costs associated with responding to Agenda: To review and evaluate grant
condition of the agency’s full applications.
this request for information will be consideration of the comment.’’ Place: Hyatt Regency Bethesda, 1 Bethesda
solely at the interested party’s expense. Consequently, this document need not Metro Center, Bethesda, MD 20814.
Not responding to this request for
sradovich on DSK3GMQ082PROD with NOTICES

be reviewed by the Office of Contact Person: Nakia C Brown, Ph.D.,
information does not preclude Management and Budget under the Scientific Review Officer, 6701 Democracy
participation in any future rulemaking authority of the PRA (44 U.S.C. 3501 et Blvd., RM 816, Bethesda, MD 20892, 301–
or procurement, if conducted. It is the seq.). 827–4905, brownnac@mail.nih.gov.
responsibility of the potential (Catalogue of Federal Domestic Assistance
responders to monitor this request for Authority: 42 U.S.C. 3501. Program Nos. 93.846, Arthritis,
information announcement for Musculoskeletal and Skin Diseases Research,
additional information pertaining to this National Institutes of Health, HHS)

VerDate Sep<11>2014 17:19 Jun 06, 2018 Jkt 244001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\07JNN1.SGM 07JNN1

Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices 26487

Dated: June 1, 2018. (HHS reference E–771–2013–1–US–01), reference E–174–2011–0–KR–10),
Sylvia L. Neal, U.S. Patent Application 61/982,051 Mexican Patent Application MX/a/
Program Analyst, Office of Federal Advisory (HHS reference E–771–2013–2–US–01), 2013/014388 (HHS reference E–174–
Committee Policy. U.S. Patent Application 61/052,665 2011–0–MX–11), Russian Patent
[FR Doc. 2018–12175 Filed 6–6–18; 8:45 am] (HHS reference E–771–2013–3–US–01), 2627216 (HHS reference E–174–2011–
BILLING CODE 4140–01–P PCT Application PCT/US2014/058941 0–RU–12), U.S. Patent 9,346,859 (HHS
(HHS reference E–771–2013–4–PCT– reference E–174–2011–0–US–13), Hong
01), U.S. Patent 9,388,222 (HHS Kong Patent Application 14106689.7
DEPARTMENT OF HEALTH AND reference E–771–2013–4–US–02), (HHS reference E–174–2011–0–HK–14),
HUMAN SERVICES Australian Patent Application U.S. Patent 9,765,123 (HHS reference E–
2014329437 (HHS reference E–771– 174–2011–0–US–15), Australian Patent
National Institutes of Health 2013–4–AU–08), Canadian Patent Application 2017200541 (HHS reference
Application 2926215 (HHS reference E– E–174–2011–0–AU–16), European
Prospective Grant of an Exclusive 771–2013–4–CA–09), Chinese Patent Patent Application 17163568.3 (HHS
Patent License: The Development of an Application 201480062185.7 (HHS reference E–174–2011–0–EP–17),
Anti-BCMA Immunotoxin for the Reference E–771–2013–4–CN–10), Japanese Patent Application 2017–
Treatment of Human Cancer European Patent Application 031283 (HHS reference E–174–2011–0–
AGENCY: National Institutes of Health, 14789449.7 (HHS reference E–771– JP–18), and U.S. Patent Application 15/
Department of Health and Human 2013–4–EP–11), Indian Patent 693,705 (HHS reference E–174–2011/0–
Services. Application 201647015226 (HHS US–24);
reference E–771–2013–4–IN–12), U.S. Patent Application 61/241,620
ACTION: Notice.
Russian Patent Application 2016114406 (HHS reference E–269–2009–0–US–01),
SUMMARY: The National Cancer Institute, (HHS reference E–771–2013–4–RU–13), PCT Application PCT/US2010/048504
an institute of the National Institutes of Japanese Patent Application (HHS (HHS reference E–269–2009–0–PCT–
Health, Department of Health and reference E–771–2013–4–JP–14), and 02), Australian Patent 2010292069 (HHS
Human Services, is contemplating the U.S. Patent Application 15/191,392 reference E–269–2009–0–AU–03),
grant of an Exclusive Patent License to (HHS reference E–771–2013–4–US–15); Canadian Patent 2773665 (HHS
practice the inventions embodied in the U.S. Patent Application 61/535,668 reference E–269–2009–0–CA–04),
Patents and Patent Applications listed (HHS reference E–263–2011–0–US–01), Chinese Patent 201080049559.3 (HHS
in the SUPPLEMENTARY INFORMATION PCT Application PCT/US2012/055034 reference E–269–2009–0–CN–05),
section of this notice to BEORO (HHS reference E–263–2011–0–PCT– European Patent 2475398 (HHS
Therapeutics, GmbH. (‘‘Beoro’’) located 02), Australian Patent 2012308591 (HHS reference E–269–2009–0–EP–06), as
in Seefeld, Germany. reference E–263–2011–0–AU–03), validated in France, Germany, Italy,
Canadian Patent Application 2846608 Spain and the United Kingdom, Indian
DATES: Only written comments and/or
(HHS reference E–263–2011–0–CA–04), Patent Application 3197/CHENP/2012
complete applications for a license European Patent 2755993 (HHS (HHS reference E–269–2009–0–IN–07),
which are received by the National reference E–263–2011–0–EP–05), U.S. Japanese Patent 5795765 (HHS reference
Cancer Institute’s Technology Transfer Patent 9,206,240 (HHS reference E–263– E–269–2009–0–JP–08), Russian Patent
Center on or before June 22, 2018 will 2011–0–US–06), Hong Kong Patent Application 2012114005 (HHS reference
be considered. Application 14111650.2 (HHS reference E–269–2009–0–RU–09), and U.S. Patent
ADDRESSES: Requests for copies of the E–263–2011–0–HK–07), U.S. Patent 8,936,792 (HHS reference E–269–2009–
patent application, inquiries, and 9,657,066 (HHS reference E–263–2011– 0–US–10);
comments relating to the contemplated 0–US–08), U.S. Patent Application 15/ U.S. Patent Application 60/969,929
an Exclusive Patent License should be 488,898 (HHS reference E–263–2011–0– (HHS reference E–292–2007–0–US–01),
directed to: David A. Lambertson, Ph.D., US–09) and European Patent PCT Application PCT/US2008/075296
Senior Technology Transfer Manager, Application 14/927,645 (HHS reference (HHS reference E–292–2007–0–PCT–
NCI Technology Transfer Center, 9609 E–263–2011–0–EP–18); 02), Australian Patent 2008296194 (HHS
Medical Center Drive, RM 1E530 MSC U.S. Patent Application 61/495,085 reference E–292–2007–0–AU–03),
9702, Bethesda, MD 20892–9702 (for (HHS reference E–174–2011–0–US–01), Canadian Patent 2698357 (HHS
business mail), Rockville, MD 20850– PCT Application PCT/US2012/041234 reference E–292–2007–0–CA–04),
9702 Telephone: (240)–276–5530; (HHS reference E–174–2011–0–PCT– European Patent 2197903 (HHS
Facsimile: (240)–276–5504 Email: 02), Australian Patent 2012268013 (HHS reference E–292–2007–0–EP–05) as
david.lambertson@nih.gov. reference E–174–2011–0–AU–03), validated in Austria, Belgium, Bulgaria,
SUPPLEMENTARY INFORMATION: Brazilian Patent Application Switzerland, Cyprus, Germany,
112013031262–9 (HHS reference E– Denmark, Estonia, Spain, Finland,
Intellectual Property 174–2011–0–BR–04), Canadian Patent France, the United Kingdom, Greece,
The following represents the Application 2838013 (HHS reference E– Croatia, Hungary, Ireland, Italy,
intellectual property to be licensed 174–2011–0–CA–05), Chinese Patent Lithuania, Luxembourg, Latvia, Monaco,
under the prospective agreement: Application 201280039071.1 (HHS Malta, the Netherlands, Norway,
U.S. Patent Application 62/255,255 reference E–174–2011–0–CN–06), Poland, Portugal, Romania, Slovenia,
(HHS reference E–010–2016–0–US–01), European Patent 2718308 (HHS Slovakia, and Turkey, U.S. Patent
sradovich on DSK3GMQ082PROD with NOTICES

U.S. Patent Application 62/257,493 reference E–174–2011–0–EP–07) as 8,871,906 (HHS reference E–292–2007–
(HHS reference E–010–2016–1–US–01), validated in Germany, Spain, France, 0–US–06), European Patent 2570425
and PCT Patent Application PCT/ the United Kingdom, and Italy, Hong (HHS reference E–292–2007–0–EP–07)
US2016/061320 (HHS reference E–010– Kong Patent Application 14105911.9 as validated in France, Germany, the
2016–2–PCT–01); (HHS reference E–174–2011–0–HK–08), United Kingdom, Italy and Spain, and
U.S. Patent Application 61/887,418 Japanese Patent 6100764 (HHS reference Hong Kong Patent Application
(HHS reference E–771–2013–0–US–01), E–174–2011–0–JP–09), South Korean 13106628.2 (HHS reference E–292–
U.S. Patent Application 61/908,464 Patent Application 2013–7032402 (HHS 2007–0–HK–08);

VerDate Sep<11>2014 17:19 Jun 06, 2018 Jkt 244001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\07JNN1.SGM 07JNN1

Document Created: 2018-06-07 00:50:25
Document Modified: 2018-06-07 00:50:25

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		June 13-14, 2018.
FR Citation		83 FR 26486

83 FR 26486 - National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 110 (June 7, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health